中国普外基础与临床杂志

中国普外基础与临床杂志

microRNA 在肝癌复发转移中的研究进展

查看全文

目的 总结 microRNA 在原发性肝细胞肝癌(hepatocellular carcinoma,HCC)复发及转移中的作用机制及其在临床中的可能的应用价值。 方法 查阅国内外的相关文献并进行综述。 结果 microRNA 在 HCC 的细胞增殖及凋亡中发挥着重要作用,不同分型的 microRNA 通过不同的作用靶点及分子通路来促进或抑制 HCC 的复发及转移。 结论 microRNA 在 HCC 的复发及转移中具有调控作用,深入研究 microRNA 在 HCC 复发及转移中的作用机制对 HCC 的复发预测及临床治疗均可提供巨大帮助,其有望成为 HCC 复发转移预测和治疗的新靶点。

Objective To summarize the mechanism of microRNA in the recurrence and metastasis of hepatocellular carcinoma (HCC) and its possible clinical application. Methods The relevant literatures at home and abroad were reviewed to summarize the results of various scholars. Results microRNA played an important role in cell proliferation and apoptosis of HCC. microRNA of different types promoted or inhibited the recurrence and metastasis of HCC through different action targets and molecular pathways. Conclusions microRNA has a regulation role in the recurrence and metastasis of HCC, and the depth mechanisms study of microRNA in the recurrence and metastasis of HCC provides great significance to clinical therapy. The miRNA is expected to be one of the new target on the prediction and treatment of recurrence and metastasis in HCC.

关键词: microRNA; 肝细胞肝癌; 复发; 转移; 综述

Key words: microRNA; hepatocellular carcinoma; recurrence; metastasis; review

引用本文: 赵英安, 李福军. microRNA 在肝癌复发转移中的研究进展. 中国普外基础与临床杂志, 2018, 25(11): 1403-1407. doi: 10.7507/1007-9424.201804075 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
2. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 2010, 15 Suppl 4: 5-13.
3. 丛文铭, 吴孟超. 肝癌术后复发发生机制及临床病理学意义. 中国实用外科杂志, 2012, 32(10): 809-811.
4. Bouyssou JM, Manier S, Huynh D, et al. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta, 2014, 1845(2): 255-265.
5. Nagy Á, Lánczky A, Menyhárt O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep, 2018, 8(1): 9227.
6. Yang N, Ekanem NR, Sakyi CA, et al. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev, 2015, 81: 62-74.
7. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev, 2015, 87: 3-14.
8. 李晞璠, 陈吉. 叉头框(FOX)基因家族的概述及进展. 世界最新医学信息文摘, 2017, 17(52): 72-73.
9. van den Brink GR, Rubin DC. Foxf2: a mesenchymal regulator of intestinal adenoma development. Gastroenterology, 2013, 144(5): 873-876.
10. Shao J, Cao J, Liu Y, et al. MicroRNA-519a promotes proliferation and inhibits apoptosis of hepatocellular carcinoma cells by targeting FOXF2. FEBS Open Bio, 2015, 5: 893-899.
11. von Felden J, Heim D, Schulze K, et al. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer, 2017, 17(1): 60.
12. Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett, 2009, 275(1): 44-53.
13. 庞立, 刘炳亚. MELK 的功能及其在肿瘤研究中的进展. 生物技术通讯, 2016, 27(1): 128-132.
14. Li Y, Li Y, Chen Y, et al. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int, 2017, 17: 102.
15. 张雨晴, 张丽慧, 魏尔清, 等. Beclin 1 在凋亡和自噬中的调节作用. 中国生物化学与分子生物学报, 2015, 31(4): 331-338.
16. Fu XT, Shi YH, Zhou J, et al. MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. Cancer Lett, 2018, 412: 108-117.
17. Vougioukalaki M, Kanellis DC, Gkouskou K, et al. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett, 2011, 304(2): 80-89.
18. Zhang X, Jiang P, Shuai L, et al. miR-589-5p inhibits MAP3K8 and suppresses CD90. J Exp Clin Cancer Res, 2016, 35(1): 176.
19. Chen H, Miao R, Fan J, et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis, 2013, 30(5): 651-658.
20. Liese J, Peveling-Oberhag J, Doering C, et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int, 2016, 29(3): 369-380.
21. Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med, 2015, 4: 6.
22. da Silva CG, Studer P, Skroch M, et al. A20 promotes liver regeneration by decreasing SOCS3 expression to enhanceIL-6/STAT3 proliferative signals. Hepatology, 2013, 57(5): 2014-2025.
23. Zheng XB, Chen XB, Xu LL, et al. miR-203 inhibits augmented proliferation and metastasis of hepatocellular carcinoma residual in the promoted regenerating liver. Cancer Sci, 2017, 108(3): 338-346.
24. Wang Y, Sun B, Zhao X, et al. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma. Oncotarget, 2016, 7(17): 24383-24401.
25. Chen WX, Zhang ZG, Ding ZY, et al. MicroRNA-630 suppresses tumor metastasis through the TGF-β- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget, 2016, 7(16): 22674-22686.
26. Zhou SL, Hu ZQ, Zhou ZJ, et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology, 2016, 63(5): 1560-1575.
27. Tatarano S, Chiyomaru T, Kawakami K, et al. Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines. Int J Oncol, 2012, 40(4): 951-959.
28. Wu SG, Huang YJ, Bao B, et al. miR-508-5p acts as an anti-oncogene by targeting MESDC1 in hepatocellular carcinoma. Neoplasma, 2017, 64(1): 40-47.
29. ten Klooster JP, Leeuwen Iv, Scheres N, et al. Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J, 2007, 26(2): 336-345.
30. Lam BD, Anthony EC, Hordijk PL. Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration. FEBS Lett, 2013, 587(2): 111-119.
31. Jin H, Yu M, Lin Y, et al. MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET. Onco Targets Ther, 2016, 9: 3281-3289.
32. Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood, 2007, 109(11): 4995-5001.
33. Lee EK, Kim DG, Kim JS, et al. Cell-cycle regulator Cks1 promotes hepatocellular carcinoma by supporting NF-κB-dependent expression of interleukin-8. Cancer Res, 2011, 71(21): 6827-6835.
34. Hu M, Wang M, Lu H, et al. Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CDC28 protein kinase regulatory subunit 1B. Oncotarget, 2016, 7(28): 43419-43431.
35. Seraj MJ, Samant RS, Verderame MF, et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res, 2000, 60(11): 2764-2769.
36. Guo Z, Li J, Sun J, et al. MiR-346 promotes HCC progression by suppressing breast cancer metastasis suppressor 1 expression. Oncol Res, 2018, [Epub ahead of print].
37. Zhang Y, Wei C, Guo CC, et al. Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis. Oncotarget, 2017, 8(63): 107237-107257.